Mednax Inc (MD) Receives a Sell from UBS

By Ryan Adsit

UBS analyst Whit Mayo maintained a Sell rating on Mednax Inc (MDResearch Report) today and set a price target of $18.00. The company’s shares closed last Monday at $23.72, close to its 52-week low of $19.93.

According to, Mayo is a 3-star analyst with an average return of 3.1% and a 50.0% success rate. Mayo covers the Services sector, focusing on stocks such as Acadia Healthcare, UnitedHealth, and Cigna Corp.

The word on The Street in general, suggests a Hold analyst consensus rating for Mednax Inc with a $23.89 average price target.

See today’s analyst top recommended stocks >>

Based on Mednax Inc’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $8.25 million. In comparison, last year the company had a net profit of $65.58 million.

Based on the recent corporate insider activity of 36 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of MD in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

MEDNAX, Inc. provides physician services including newborn, anesthesia, maternal-fetal, tele radiology, pediatric cardiology and other pediatric subspecialty care. The company’s solution include anesthesiology & pain management, prenatal, neonatal, pediatric, radiology, tele radiology, revenue cycle management and perioperative improvement consulting.